Abstract:Nasopharyngeal carcinoma (NPC) is a common type of cancer in South East Asia with peculiar epidemiology, pathology, clinical behavior and response to treatment characteristics. To the best of our knowledge, this is the first study to investigate the use of a contrast-enhanced ultrasound (CEUS) as a predictor for the therapeutic response in lymph node metastases of NPC patients treated with radiation-based therapy. Sixty-seven NPC patients with lymph node metastases underwent the lymph nodes CEUS examination twice; pre- and in-treatment (at the 5th fraction radiotherapy), respectively. The CEUS parameters were acquired through Qontrast_4.0 software and mainly included peak intensity (PI) and time to peak (TTP). The response assessment at the lymph nodes revealed a complete response (CR) in 48 patients and partial response (PR) in 19 patients. There was a significant difference in pre-treatment PI (PIpre) between the patients who showed CR or PR, but the predicted sensitivity and specificity of PIpre was low. The mean in-treatment PI (PIin) value of the lymph nodes that achieved a CR was 34.24±3.78%, which was significantly higher than the PIin value for PR, 25.62±2.30% (P<0.001). Furthermore, the PIratio, a PI-quotient, was calculated by dividing the PIin by the corresponding PIpre. The higher PIratio was also observed in CR lymph nodes (0.81±0.01 vs. 0.66±0.01; P=0.001), and the mean change in PI (PIΔ; PIΔ = PIpre-PIin) was smaller in the patients with CR nodes compared to the patients with PR nodes (7.79±3.28 vs. 13.77±1.90%; P=0.000). No difference was observed in TTPpre or TTPin between the CR or PR lymph nodes patients. A receiver operating characteristic curve was constructed to assess the accuracy of the parameters for the prediction of the therapeutic responses. The sensitivity and specificity of PIin in predicting the therapeutic response was 94.3 and 88.2%, and the corresponding figures of the PIratio were 92.5 and 83.8%, respectively. The CEUS parameters during the early course of radiation-based therapy, PIin and PIratio, are associated with the therapeutic response of NPC lymph node metastases, with a high predicted sensitivity and specificity, thus yielding the conceivable predictors with the potential to individualize treatment.

Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy.

Identification of Prognostic Biomarkers for Response to Radiotherapy by DNA Microarray in Nasopharyngeal Carcinoma Patients

Parametric Contrast-Enhanced Ultrasound As an Early Predictor of Radiation-Based Therapeutic Response for Lymph Node Metastases of Nasopharyngeal Carcinoma.

Identification of ERp29 As a Biomarker for Predicting Nasopharyngeal Carcinoma Response to Radiotherapy

Sp1 is Over-Expressed in Nasopharyngeal Cancer and is a Poor Prognostic Indicator for Patients Receiving Radiotherapy.

A Five-Variable Signature Predicts Radioresistance and Prognosis in Nasopharyngeal Carcinoma Patients Receiving Radical Radiotherapy

Identification of Serum Biomarkers for Nasopharyngeal Carcinoma by Proteomic Analysis.

Radiosensitivity-Related Genes and Clinical Characteristics of Nasopharyngeal Carcinoma

Prognostic Value of a Serum Panel of Inflammatory Factors in Non-Metastatic Nasopharyngeal Carcinoma Patients Undergoing Radical Radiotherapy with Adjuvant Chemotherapy

Multivariate analysis of prognostic makers in patients with nasopharyngeal carcinoma intreatment of radiotherapy combined with induction chemotherapy]

Identifying biomarkers for nasopharyngeal carcinoma diagnosis and chemoradiotherapy response using serum endogenous small molecules profiling

Extensive Serum Biomarker Analysis in Patients with Nasopharyngeal Carcinoma.

Serum CCL2 and Serum TNF-α – Two New Biomarkers Predict Bone Invasion, Post-Treatment Distant Metastasis and Poor Overall Survival in Nasopharyngeal Carcinoma

Study on the radiotherapy effect and serum neutral granulocyte lymphocyte ratio and inflammatory factor expression of nasopharyngeal carcinoma

A metabolic discrimination model for nasopharyngeal carcinoma and its potential role in the therapeutic evaluation of radiotherapy

Annexin A1: a New Biomarker for Predicting Nasopharyngeal Carcinoma Response to Radiotherapy.

Key radioresistance regulation models and marker genes identified by integrated transcriptome analysis in nasopharyngeal carcinoma

Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy.

Comparative Serum Proteomic Analysis Involving Liver Organ-Specific Metastasis-Associated Proteins Of Nasopharyngeal Carcinoma

Assessment of the Radiotherapy Effect for Nasopharyngeal Cancer Using Plasma Surface-Enhanced Raman Spectroscopy Technology

Dynamic of Serum Levels of VEGF in Nasopharyngeal Patients in Course of Radiotherapy